Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06068764 · ClinicalTrials.gov registry record · Phase 4

Etomidate Versus Propofol in CABG Surgery

A Phase 4 study of Coronary Artery Disease, sponsored by Hartford Hospital.

Recruiting
Registry status
Phase 4
Development phase
300
Enrollment target
1
Study location

NCT06068764 is a Phase 4 study of Coronary Artery Disease that is actively recruiting participants, run by Hartford Hospital. The registered enrollment target is 300 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06068764, a Phase 4 study of Coronary Artery Disease, is actively recruiting participants, sponsored by Hartford Hospital.

RECRUITING
Registry status
Phase 4
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The objective of this single-blinded randomized controlled interventional clinical trial is to learn about the efficacy and long-term safety of etomidate compared to propofol as an anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG) surgery. The primary aim of this study is to determine whether patients receiving etomidate or propofol exhibit similar requirements for vasopressor or ionotropic agents during both the intraoperative and postoperative periods. To achieve this goal, participants who are scheduled for CABG surgery will be randomly assigned to receive either etomidate or propofol as the principal hypnotic agent. The researchers will then compare the effects of these two anesthesia induction agents on various factors, including the need for hemodynamic support, hemodynamic stability, duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and overall hospital length of stay. Additionally, they will assess whether there are disparities in mortality rates and readmission rates within a 6-month timeframe after the surgery. By comparing the outcomes between the two groups, the study aims to provide valuable insights into the potential differences in vasopressor or ionotropic agent requirements between etomidate and propofol. This information can help inform clinical decision-making and potentially optimize anesthesia management strategies for patients undergoing CABG surgery.

Conditions Studied

Coronary Artery Disease

Interventions

  • DRUG Propofol
  • DRUG Etomidate

Study Locations (1)

Connecticut

  • Hartford Hospital - Hartford

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-12-05
Est. Completion 2026-08
Phase Phase 4

Sponsor

Hartford Hospital

75 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06068764

The ClinicalTrials.gov registry entry for NCT06068764 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (77% lower). The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Propofol is the first listed.

NCT06068764 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT06068764 about?

NCT06068764 is a clinical study titled "Etomidate Versus Propofol in CABG Surgery". The objective of this single-blinded randomized controlled interventional clinical trial is to learn about the efficacy and long-term safety of etomidate compared to propofol as an anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG) surgery. The primary aim of this ...

What is the current status of trial NCT06068764?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2023-12-05. Estimated completion is 2026-08.

What conditions does trial NCT06068764 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT06068764?

The interventions under investigation include: Propofol (DRUG), Etomidate (DRUG).

Who is sponsoring clinical trial NCT06068764?

This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06068764 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.